Similar safety and efficacy of once- and twice-daily lopinavir/ritonavir tablets in treatment-experienced HIV-1-infected subjects at 48 weeks.

Roberto Zajdenverg,Thomas J Podsadecki,Sharlaa Badal-Faesen,Jaime Andrade-Villanueva,Joseph Gathe, Horacio Mingrone,Linda M Fredrick, Isabelle A Gaultier, W Chris Woodward,Barry M Bernstein

Journal of Acquired Immune Deficiency Syndromes（2010）

引用 32|浏览17

暂无评分

摘要

LPV/r dosed QD resulted in increased treatment adherence and was as efficacious as BID LPV/r while providing similar safety, tolerability, and limited resistance evolution.

查看译文

关键词

HIV-1,highly-active antiretroviral therapy,HIV protease inhibitors,treatment experienced,once daily

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要